- Home
- SPB vs PHVS Comparison
SPB vs PHVS Comparison
Compare SPB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPB | PHVS |
|---|---|---|
| Founded | 1906 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SPB | PHVS |
|---|---|---|
| Price | $74.11 | $25.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $82.40 | $40.70 |
| AVG Volume (30 Days) | ★ 302.0K | 103.8K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $3,802,100,000.00 | N/A |
| Revenue This Year | $1.78 | N/A |
| Revenue Next Year | $1.85 | N/A |
| P/E Ratio | $57.60 | ★ N/A |
| Revenue Growth | ★ 20.86 | N/A |
| 52 Week Low | $49.99 | $11.51 |
| 52 Week High | $80.42 | $29.80 |
Technical Indicators
Market Signals| Indicator | SPB | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 50.58 | 41.92 |
| Support Level | $73.99 | $24.25 |
| Resistance Level | $80.42 | $28.06 |
| Average True Range (ATR) | 2.26 | 1.17 |
| MACD | -0.71 | -0.14 |
| Stochastic Oscillator | 62.69 | 12.71 |
Price Performance
Historical ComparisonAbout SPB Spectrum Brands Holdings Inc.
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, global Pet Care, and Home and Garden. The Company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.